Answers are grounded in this paper and cite their sources.
Background Preclinical evidence suggests that co‐administration of the 5‐HT1A agonist buspirone and the 5‐HT1B/1D agonist zolmitriptan act synergistically to reduce dyskinesia to a greater extent than that achieved by either drug alone. Objectives Assess the therapeutic potential of a fixed‐dose buspirone and zolmitriptan combination in Parkinson's disease (PD) patients with levodopa‐induced dyskinesia. Methods Single‐center, randomized, placebo‐controlled, two‐way crossover study (NCT02439203) of a fixed‐dose buspirone/zolmitriptan regimen (10/1.25 mg three times a day) in 30 patients with PD experiencing at least moderately disabling peak‐effect dyskinesia. Results Seven days of treatment with buspirone/zolmitriptan added to levodopa significantly reduced dyskinesia as assessed by Abnormal Involuntary Movement Scale scores versus placebo (mean treatment effect vs. placebo: −4.2 [−6.1, −2.3]) without significantly worsening Unified Parkinson's Disease Rating Scale (UPDRS) Part III (ON) scores (mean treatment effect vs. placebo: 0.6 [−0.1, 1.3]). No serious adverse events were reported. Conclusions In this proof‐of‐concept study, addition of buspirone/zolmitriptan to the patients’ PD medication regimen significantly reduced dyskinesia severity without worsening motor function.
No takes yet. Share an insight, caveat, or question.
LeWitt et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: